Clostridioides Difficile Infections (CDI) Market Insights Report 2025: Robust Pipeline Of 48 Molecules, Especially Those In Phase III

(MENAFN- GlobeNewsWire - Nasdaq) Key opportunities in CDI therapeutics include leveraging the robust pipeline of 48 molecules, especially those in Phase III, forming strategic partnerships to benefit from North America's trend, and capitalizing on acquisition trends in Europe to enhance market positioning.

Dublin, Sept. 22, 2025 (GLOBE NEWSWIRE) -- The "Clostridioides difficile Infections (CDI): Market View" report has been added to ResearchAndMarkets's offering.
This reports provides a data-driven overview of the current and future competitive landscape in CDI Therapeutics.
In 2024, there were more than 2.04 million diagnosed incident cases of CDI in the 16 countries covered in the analyst's epidemiology forecast. The current CDI market is dominated by several companies marketing genericized antibiotic therapies.
The CDI pipeline holds 48 molecules, with five molecule present in Phase III development. Over the past 10 years, commercial sponsors headed trials for CDI, led by Pfizer (seven trials).
Over the past decade, partnerships have accounted for a significant portion of transactions in North America, representing 28.6% of the total deals. In contrast, Europe has seen acquisitions dominate, making up 40% of the deals.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the CDI Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global CDI Therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.

Key Topics Covered:
1 Preface
1.1 Contents
1.2 Report Scope
1.3 List of Tables and Figures
1.4 Abbreviations
2 Key Findings
3 Disease Landscape
3.1 Disease Overview
3.2 Epidemiology Overview
3.3 Treatment Overview
4 Marketed Drugs Assessment
4.1 Leading Marketed Drugs
4.2 Overview by Mechanism of Action
4.3 Overview by Molecule Type
4.4 Product Profiles and Sales Forecast
5 Pricing and Reimbursement Assessment
5.1 Annual Cost of Therapy
5.2 Time to Pricing and Reimbursement
6 Pipeline Drugs Assessment
6.1 Mid-to-late-stage Pipeline Drugs
6.2 Overview by Development Stage
6.3 Overview by Mechanism of Action
6.4 Overview by Molecule Type
6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
6.6 Therapy Area and Indication-specific PTSR and LoA
7 Clinical Trials Assessment
7.1 Historical Overview
7.2 Overview by Phase
7.3 Overview by Status
7.4 Overview by Phase for Ongoing and Planned Trials
7.5 Trials with Virtual Components
7.6 Overview of Trials by Geography
7.7 Single-Country and Multinational Trials by Region
7.8 Top 20 Sponsors with Breakdown by Phase
7.9 Top 20 Sponsors with Breakdown by Status
7.10 Overview by Endpoint Status
7.11 Overview by Race and Ethnicity
7.12 Enrollment Data
7.13 Top 20 countries for Trial Sites
7.14 Top 20 Sites Globally
7.15 Feasibility Analysis - Geographic Overview
7.16 Feasibility Analysis - Benchmark Models
8 Deals Landscape
8.1 Mergers, Acquisitions, and Strategic Alliances by Region
8.2 Recent Mergers, Acquisitions, and Strategic Alliances
9 Commercial Assessment
9.1 Key Market Players
10 Future Market Catalysts
11 Appendix
For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN22092025004107003653ID1110094456